Please login to the form below

Not currently logged in
Email:
Password:

UK is first to receive Roche's rare lung cancer drug

Alecensa made available under MHRA's early access scheme

Roche

Roche’s lung cancer drug Alecensa (alectinib) has been approved for early access in the UK under an MHRA scheme that allows it to reach patients prior to gaining a European licence.

The oral drug has been developed for people with non-small cell lung cancer (NSCLC) whose tumours are identified as ALK-positive, without the need for prior chemotherapy.

The UK will now be the first country in Europe to access Alecensa, following the MHRA’s positive scientific approval under its Early Access to Medicines Scheme (EAMS).

The scheme - which was introduced in 2014 - allows patients and doctors access to ‘innovative’ treatments for serious medical conditions where there is a clear current unmet medical need.

Roche UK’s medical director Rav Seeruthun said: “We are delighted that we are able to make alectinib available to patients with this rare type of lung cancer in the UK via EAMS.”

In the UK, more than 45,000 people are diagnosed with lung cancer annually, with approximately 4-5% patients that are identified with advanced NSCLC are ALK-positive.

Seeruthun added: “Our mission is to discover treatments that are beyond the standard of care, and we work tirelessly to be able to make them available to patients in the UK.”

The approval was based on the back of the ALEX study, an open-label, randomised phase III head-to-head trial which compared the efficacy and safety between alectinib and crizotinib in patients who had not previously received treatment.

Data from the study showed that patients taking Alecensa had significantly prolonged progression-free survival when compared with Pfizer’s Xalkori (crizotinib), reducing risk of progression/death by 53%.

Alecensa is still being assessed for marketing authorisation by the EMA, and Roche said it expects an official license later this year.

The Swiss pharma firm said it would “continue to work collaboratively and flexibly with NICE and NHS England to achieve sustained access for alectinib”.

Article by
Gemma Jones

7th September 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

OUTiCO Case Study - Product Launch
POSITIVE FORMULARY SUCCESS WITHIN 8 MONTHS!...
An insight into Multi-Channel Account Management
At OUTiCO we often talk about moving away from traditional methods, embracing change, and offering an exceptional outsourcing service, but what does that mean day to day?...
14_ipad_lowres.jpg
Why AI might be the rep’s best friend
When looking for the next big thing in digital communication, there’s nothing bigger than the sweeping changes promised by artificial intelligence. There’s little doubt that AI is coming to pharma...

Infographics